Loading...
•
Dec 31, 2025
Emergent BioSolutions Q4 2025 Earnings Report
Emergent BioSolutions reported fourth quarter 2025 financial results, showing a revenue decline of 24% year-over-year and a net loss of $54.6 million.
Key Takeaways
Emergent BioSolutions faced a challenging fourth quarter with total revenues falling to $148.7 million, primarily driven by a 41% drop in Naloxone sales due to generic competition. Despite the quarterly loss, the company achieved full-year profitability with net income of $52.6 million and reduced its debt by $100 million as part of its multi-year turnaround strategy.
Total revenues for Q4 2025 decreased 24% to $148.7 million compared to $194.7 million in Q4 2024.
Naloxone product sales fell 41% due to increased generic competition impacting price and unit sales.
The company made a voluntary debt payment of $100 million toward its Term Loan Principal during the year.
Full-year 2025 results showed a significant turnaround with net income of $52.6 million compared to a $190.6 million loss in 2024.
Revenue by Segment
Forward Guidance
For the full year 2026, Emergent expects total revenues between $720 million and $760 million, with a focus on international expansion and operational efficiency.
Positive Outlook
- Expected total revenues of $720M - $760M for FY 2026.
- Anticipated Adjusted EBITDA of $135M - $155M.
- Expansion into international markets with MCM biodefense business.
- Maintaining market leadership in the naloxone category.
- Targeted R&D spend of 6% to 7% of revenues to drive organic growth.
Challenges Ahead
- Forecasted GAAP net loss of $(30)M to $(10)M for FY 2026.
- Expected decline in total adjusted gross margin to 45% - 47%.
- Continued pressure from generic competition in the naloxone market.
- Q1 2026 revenue forecast of $135M - $155M indicates a slow start to the year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...